Christian Hundhausen
Research Subjects
Research Interests
Christian Hundhausen has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jane Hoyt Buckner
Center for Translational Immunology Benaroya Research Institute Seattle Washington USA
2 shared publications - Alex K. Hu
Center for Systems Immunology, Benaroya Research Institute, Seattle, Washington
1 shared publication - Anne M. Hocking
Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101, USA
1 shared publication Anne Petz
Institute for Pharmacology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, Düsseldorf 40225, Germany
1 shared publication- Britta E. Jones
Center for Translational Immunology
1 shared publication - Carla J. Greenbaum
Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, USA
1 shared publication
Latest Publications
- Open Access
- 22 November 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (22)
IL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function
Therapeutics that inhibit IL-6 at different points in its signaling pathway are in clinical use, yet whether the immunological effects of these interventions differ based on their molecular target is unknown. We performed short-term interventions in individuals with type 1 diabetes using anti–IL-6 (siltuximab) or anti–IL-6 receptor (IL-6R; tocilizumab) therapies and investigated the impact of this in vivo blockade on T cell fate and function. Immune outcomes were influenced by the target of the therapeutic intervention (IL-6 versus IL-6R) and by peak drug concentration. Tocilizumab reduced ICOS expression on T follicular helper cell populations and T cell receptor–driven (TCR-driven) STAT3 phosphorylation. Siltuximab reversed resistance to Treg-mediated suppression and increased TCR-driven phosphorylated STAT3 and production of IL-10, IL-21, and IL-27 by T effectors. Together, these findings indicate that the context of IL-6 blockade in vivo drives distinct T cell–intrinsic changes that may influence therapeutic outcomes.
- 22 November 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (22)
Open AccessIL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function
Therapeutics that inhibit IL-6 at different points in its signaling pathway are in clinical use, yet whether the immunological effects of these interventions differ based on their molecular target is unknown. We performed short-term interventions in individuals with type 1 diabetes using anti–IL-6 (siltuximab) or anti–IL-6 receptor (IL-6R; tocilizumab) therapies and investigated the impact of this in vivo blockade on T cell fate and function. Immune outcomes were influenced by the target of the therapeutic intervention (IL-6 versus IL-6R) and by peak drug concentration. Tocilizumab reduced ICOS expression on T follicular helper cell populations and T cell receptor–driven (TCR-driven) STAT3 phosphorylation. Siltuximab reversed resistance to Treg-mediated suppression and increased TCR-driven phosphorylated STAT3 and production of IL-10, IL-21, and IL-27 by T effectors. Together, these findings indicate that the context of IL-6 blockade in vivo drives distinct T cell–intrinsic changes that may influence therapeutic outcomes.
- 23 August 2022
- Published by Elsevier in Matrix Biology
- Vol. 112, 116-131
Hyaluronan synthase 3 is protective after cardiac ischemia-reperfusion by preserving the T cell response
- 23 August 2022
- Published by Elsevier in Matrix Biology
- Vol. 112, 116-131
Hyaluronan synthase 3 is protective after cardiac ischemia-reperfusion by preserving the T cell response
- 1 October 2021
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 41 (10) , 2551-2562
Endothelial Hyaluronan Synthase 3 Augments Postischemic Arteriogenesis Through CD44/eNOS Signaling
Objective: The dominant driver of arteriogenesis is elevated shear stress sensed by the endothelial glycocalyx thereby promoting arterial outward remodeling. Hyaluronan, a critical component of the endothelial glycocalyx, is synthesized by 3 HAS isoenzymes (hyaluronan synthases 1-3) at the plasma membrane. Considering further the importance of HAS3 for smooth muscle cell and immune cell functions we aimed to evaluate its role in collateral artery growth. Approach and Results: Male Has3 -deficient ( Has3 -KO) mice were subjected to hindlimb ischemia. Blood perfusion was monitored by laser Doppler perfusion imaging and endothelial function was assessed by measurement of flow-mediated dilation in vivo. Collateral remodeling was monitored by high resolution magnetic resonance angiography. A neutralizing antibody against CD44 (clone KM201) was injected intraperitoneally to analyze hyaluronan signaling in vivo. After hindlimb ischemia, Has3 -KO mice showed a reduced arteriogenic response with decreased collateral remodeling and impaired perfusion recovery. While postischemic leukocyte infiltration was unaffected, a diminished flow-mediated dilation pointed towards an impaired endothelial cell function. Indeed, endothelial AKT (protein kinase B)-dependent eNOS (endothelial nitric oxide synthase) phosphorylation at Ser1177 was substantially reduced in Has3 -KO thigh muscles. Endothelial-specific Has3 -KO mice mimicked the hindlimb ischemia-induced phenotype of impaired perfusion recovery as observed in global Has3 -deficiency. Mechanistically, blocking selectively the hyaluronan binding site of CD44 reduced flow-mediated dilation, thereby suggesting hyaluronan signaling through CD44 as the underlying signaling pathway. Conclusions: In summary, HAS3 contributes to arteriogenesis in hindlimb ischemia by hyaluronan/CD44-mediated stimulation of eNOS phosphorylation at Ser1177. Thus, strategies augmenting endothelial HAS3 or CD44 could be envisioned to enhance vascularization under pathological conditions.
- 1 October 2021
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 41 (10) , 2551-2562
Endothelial Hyaluronan Synthase 3 Augments Postischemic Arteriogenesis Through CD44/eNOS Signaling
Objective: The dominant driver of arteriogenesis is elevated shear stress sensed by the endothelial glycocalyx thereby promoting arterial outward remodeling. Hyaluronan, a critical component of the endothelial glycocalyx, is synthesized by 3 HAS isoenzymes (hyaluronan synthases 1-3) at the plasma membrane. Considering further the importance of HAS3 for smooth muscle cell and immune cell functions we aimed to evaluate its role in collateral artery growth. Approach and Results: Male Has3 -deficient ( Has3 -KO) mice were subjected to hindlimb ischemia. Blood perfusion was monitored by laser Doppler perfusion imaging and endothelial function was assessed by measurement of flow-mediated dilation in vivo. Collateral remodeling was monitored by high resolution magnetic resonance angiography. A neutralizing antibody against CD44 (clone KM201) was injected intraperitoneally to analyze hyaluronan signaling in vivo. After hindlimb ischemia, Has3 -KO mice showed a reduced arteriogenic response with decreased collateral remodeling and impaired perfusion recovery. While postischemic leukocyte infiltration was unaffected, a diminished flow-mediated dilation pointed towards an impaired endothelial cell function. Indeed, endothelial AKT (protein kinase B)-dependent eNOS (endothelial nitric oxide synthase) phosphorylation at Ser1177 was substantially reduced in Has3 -KO thigh muscles. Endothelial-specific Has3 -KO mice mimicked the hindlimb ischemia-induced phenotype of impaired perfusion recovery as observed in global Has3 -deficiency. Mechanistically, blocking selectively the hyaluronan binding site of CD44 reduced flow-mediated dilation, thereby suggesting hyaluronan signaling through CD44 as the underlying signaling pathway. Conclusions: In summary, HAS3 contributes to arteriogenesis in hindlimb ischemia by hyaluronan/CD44-mediated stimulation of eNOS phosphorylation at Ser1177. Thus, strategies augmenting endothelial HAS3 or CD44 could be envisioned to enhance vascularization under pathological conditions.
- Open Access
- 1 May 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 196 (1_Suppleme) , 48.2
The IFIH1 A946T autoimmune risk variant exhibits enhanced signaling and promotes T1D pathogenesis
Genome wide association studies have linked SNPs in innate signaling programs to an increased risk for autoimmune disease. One SNP, rs1990760, within the IFIH1 viral sensor (leading to an A to T amino acid change at codon 946) is strongly associated with multiple autoimmune diseases including type 1 diabetes (T1D). The impact of this variant on viral sensing and autoimmune pathogenesis, however, has not yet been determined. Using an overexpression system, we demonstrate that IFIH1-A946T exhibits heightened basal and post-stimulation signaling and increased viral control. Consistent with this finding, primary PBMCs from healthy subjects expressing the variant exhibit heightened signaling. To study IFIH1-A946T in vivo, we generated a novel knock-in murine model. Both heterozygous and homozygous variant mice display enhanced basal Type I IFN mRNA expression and splenomegaly. Moreover, homozygous pups manifest an embryonic survival defect. Further, IFIH1-T946 mice exhibit increased frequency of STZ-induced T1D. Finally, intercross of IFIH1-T946 mice with animals expressing the T1D risk variant in PTPN22 lead to a synergistic increase in T1D development. Together, our data demonstrate that IFIH1-A946T alters antiviral signaling and strongly supports the model that increased Type I IFN production driven by the variant leads to an inflammatory state that promotes autoimmunity, particularly in association with other autoimmune risk alleles.
- 1 May 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 196 (1_Suppleme) , 48.2
Open AccessThe IFIH1 A946T autoimmune risk variant exhibits enhanced signaling and promotes T1D pathogenesis
Genome wide association studies have linked SNPs in innate signaling programs to an increased risk for autoimmune disease. One SNP, rs1990760, within the IFIH1 viral sensor (leading to an A to T amino acid change at codon 946) is strongly associated with multiple autoimmune diseases including type 1 diabetes (T1D). The impact of this variant on viral sensing and autoimmune pathogenesis, however, has not yet been determined. Using an overexpression system, we demonstrate that IFIH1-A946T exhibits heightened basal and post-stimulation signaling and increased viral control. Consistent with this finding, primary PBMCs from healthy subjects expressing the variant exhibit heightened signaling. To study IFIH1-A946T in vivo, we generated a novel knock-in murine model. Both heterozygous and homozygous variant mice display enhanced basal Type I IFN mRNA expression and splenomegaly. Moreover, homozygous pups manifest an embryonic survival defect. Further, IFIH1-T946 mice exhibit increased frequency of STZ-induced T1D. Finally, intercross of IFIH1-T946 mice with animals expressing the T1D risk variant in PTPN22 lead to a synergistic increase in T1D development. Together, our data demonstrate that IFIH1-A946T alters antiviral signaling and strongly supports the model that increased Type I IFN production driven by the variant leads to an inflammatory state that promotes autoimmunity, particularly in association with other autoimmune risk alleles.